Table 4 |
||
| Adjuvant chemotherapy and patient/tumour characteristics | ||
| pT1a, pT1b total patients (N = 402) | Patients treated with adjuvant chemotherapy (N = 127)* | |
| Distribution by age | ||
| 18–34 | 7/402 (1.7%) | 6/7 (85.7%) |
| 35–49 | 85/402 (21.1%) | 46/85 (54.1%) |
| 50–69 | 230/402 (57.2%) | 67/230 (29.1%) |
| ≥ 70 | 80/402 (19.9%) | 8/80 (10.0%) |
| Menopausal status | ||
| Pre- | 101/402 (25.1%) | 52/101 (51.5%) |
| Post- | 293/402 (72.8%) | 72/293 (24.6%) |
| Unknown | 8/402 (2.0%) | 3/8 (37.5%) |
| Grading | ||
| G1 | 101/402 (25.1%) | 9/101 (8.9%) |
| G2 | 221/402 (55.0%) | 66/221 (29.8%) |
| G3 | 72/402 (17.9%) | 49/72 (68.0%) |
| Unknown | 8/402 (2.0%) | 3/8 (37.5%) |
| Proliferation index (Ki-67/MB1) | ||
| 0–18% | 283/402 (70.6%) | 55/283 (19.4%) |
| 19–29% | 52/402 (12.9%) | 28/53 (52.8%) |
| ≥ 30% | 54/402 (13.4%) | 41/54 (75.9%) |
| Unknown | 13/402 (3.2%) | 3/13 (23.0%) |
| ER status | ||
| ER positive (≥ 10%) | 351 /402(87.3%) | 82/351(23.6%) |
| ER negative (0–9%) | 51/402(12.7%) | 45/51 (88.2%) |
| Hormonal status* | ||
| ER and/or PgR positive | 354 /402 (74.6%) | 84/354 (24.0%) |
| ER and PgR negative | 48/402 (25.4%) | 43/48 (89.6%) |
| HER2 status** | ||
| Positive | 49/402 (12.2%) | 36/49 (73.5%) |
| Negative | 344/402 (85.6%) | 90/344 (26.2%) |
| Missing | 9/402 (2.2%) | 1/9 (11.1%) |
| pN status | ||
| pN0 | 319/402 (79.4%) | 72/319 (22.6%) |
| pN1 (1–3) | 74/402 (18.4%) | 47/74 (63.5%) |
| pN2 (4–9) | 6/402(1.5%) | 5/6 (83.3%) |
| pN3 (≥ 10) | 3/402 (0.7%) | 3/3 (100%) |
* cut off: 10%
** HER2 status positive if: IHC 3+; or IHC 2+ and amplified by FISH,SISH,CISH; or amplified by FISH,SISH,CISH
Gori et al. BMC Cancer 2012 12:158 doi:10.1186/1471-2407-12-158
